高危前列腺癌强化新辅助治疗后长期结局及残余肿瘤负荷的预后影响
本研究分析本院2006至2018年五项试验中接受6个月雄激素受体通路抑制剂新辅助治疗的高危局限性前列腺癌患者数据,以残余肿瘤负荷量化病理反应。218例患者5年无转移生存率为83%,残余肿瘤负荷越高无转移生存越差,且可区分不同风险组。
要点
- 218例高危局限性前列腺癌患者接受6个月雄激素受体通路抑制剂新辅助治疗后行根治性前列腺切除术,5年无转移生存率为83%。
- 残余肿瘤负荷越高,无转移生存越差(风险比1.21,95%置信区间1.01-1.47)。
- 残余肿瘤负荷0、1、2、3组的5年无转移生存率分别为100%、90%、82%和63%。
核心结论
- 高危局限性前列腺癌患者接受雄激素受体通路抑制剂新辅助治疗后行根治性前列腺切除术,5年无转移生存率为83%。
- 以残余肿瘤负荷评估的病理反应深度对无转移生存具有高度预后价值。
- 残余肿瘤负荷可用于指导高危局限性前列腺癌的新辅助治疗及新辅助治疗后辅助治疗试验。
研究设计与样本
- 分析本院2006至2018年五项评估6个月雄激素受体通路抑制剂新辅助治疗高危局限性前列腺癌试验中接受治疗的患者数据。
- 残余肿瘤负荷量化为经细胞密度校正的原发肿瘤计算体积。
- 主要结局为基于常规影像的无转移生存。
- 采用Contal-O'Quigley方法探索残余肿瘤负荷分类以区分无转移生存高危和低危组。
主要发现
- 218例 eligible 患者中,诊断时前列腺特异性抗原中位值为8 ng/ml,42例(20%)为cT3-4期疾病,154例(71%)活检Gleason评分为8-10分。
- 根治性前列腺切除术时,24例(11%)达到病理完全缓解,残余肿瘤负荷中位值为0.05 cm3(四分位距0.00-0.32)。
- 中位随访5年时,45例发生转移,11例死亡,5年无转移生存率为83%(95%置信区间77-88%)。
- 多变量分析中,较高的残余肿瘤负荷与较差的无转移生存相关(风险比1.21,95%置信区间1.01-1.47)。
- 残余肿瘤负荷0组(病理完全缓解或无残留疾病)、1组(<0.003 cm3)、2组(0.003-0.672 cm3)和3组(≥0.672 cm3)的5年无转移生存率分别为100%、90%(95%置信区间72-97%)、82%(95%置信区间73-88%)和63%(95%置信区间40-79%)。
临床怎么用
- 原文结论指出残余肿瘤负荷可用于指导高危局限性前列腺癌的新辅助治疗及新辅助治疗后辅助治疗试验。
局限性
- 关键局限性为缺乏验证队列。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Long-term outcomes and the prognostic impact of the extent of residual disease after neoadjuvant therapy (NAT) with androgen deprivation therapy (ADT) and an androgen receptor pathway inhibitor (ARPI) before radical prostatectomy (RP) for high-risk localized prostate cancer (HRLPC) are not known. METHODS: We analyzed data for patients treated in five trials evaluating 6 mo of ARPI NAT for HRLPC at our institution between 2006 and 2018. Residual cancer burden (RCB) was quantitated as the calculated tumor volume adjusted for cellularity in the primary tumor. The primary outcome was metastasis-free survival (MFS) according to conventional imaging. We explored RCB categories using the Contal-O'Quigley method to distinguish high- and low-risk groups for MFS. KEY FINDINGS AND LIMITATIONS: Among 218 eligible patients, median prostate-specific antigen at diagnosis was 8 ng/ml, 42 (20%) had cT3-4 disease, and 154 (71%) had a biopsy Gleason score of 8-10. At RP, 24 (11%) had a pathologic complete response and median RCB was 0.05 cm3 (interquartile range 0.00-0.32). By median follow-up of 5 yr, 45 patients had developed metastases and 11 died; the 5-yr MFS rate was 83% (95% confidence interval [CI] 77-88%). On multivariable analysis, higher RCB was associated with poorer MFS (hazard ratio 1.21, 95% CI 1.01-1.47). The 5-yr MFS rates were 100%, 90% (95% CI 72-97%), 82% (95% CI 73-88%), and 63% (95% CI 40-79%) for patients with RCB-0 (a pathologic complete response or no residual disease), RCB-1 (<0.003 cm3), RCB-2 (0.003-0.672 cm3), and RCB-3 (≥0.672 cm3), respectively. The key limitation is lack of a validation cohort. CONCLUSIONS AND CLINICAL IMPLICATIONS: The 5-yr MFS rate for patients treated with ARPI NAT before RP for HRLPC was 83%. The depth of pathologic response, evaluated as the RCB, was highly prognostic for MFS. RCB could be used to guide NAT and post-NAT adjuvant trials in HRLPC.
引用
- Ravi P, Kwak L, Acosta AM, et al. Long-term Outcomes and Prognostic Impact of Residual Cancer Burden After Intensified Neoadjuvant Therapy in High-risk Prostate Cancer. Eur Urol. 2025. PMID: 39920004. doi:10.1016/j.eururo.2025.01.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。